Short term administration of gonadotropin-releasing hormone analog to a patient with a testosterone-secreting ovarian tumor.
A GnRH superagonist, buserelin, was administered for 16 days to a postmenopausal woman with a testosterone-secreting ovarian tumor. Serum gonadotropin levels decreased by more than 70%, and serum testosterone fell by more than 50%. This short term study demonstrates that in these uncommon tumors androgen secretion is gonadotropin sensitive, and suggests that GnRH analogs may have therapeutic value in such patients.
D000281:Administration, Intranasal; D002064:Buserelin / Q000627:therapeutic use*; D006063:Chorionic Gonadotropin; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007984:Leydig Cell Tumor / Q000097:blood / Q000378:metabolism*; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000378:metabolism*; D010906:Pituitary Hormone-Releasing Hormones / Q000627:therapeutic use*; D013739:Testosterone / Q000097:blood / Q000378:metabolism*
D006063:Chorionic Gonadotropin; D010906:Pituitary Hormone-Releasing Hormones; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin